Essilor Supports the Planned Friendly Bid for Sperian Protection

By Essilor, PRNE
Tuesday, March 30, 2010

CHARENTON-LE-PONT, France, March 31, 2010 - Essilor International announced today that it has signed an
agreement with the Cinven Investment Fund and Mrs. Ginette Dalloz concerning
Essilor's 15.05% stake (23.21% voting rights) in Sperian Protection.
According to the terms of the deal and subject to certain conditions, Cinven
will launch a cash tender offer for Sperian Protection through a holding
company (Menelas France) under its control.

Essilor has agreed to tender all of its shares in Sperian
Protection to Menelas France, based on the offered price per share, provided
that, at the end of the offer period, Menelas France holds 57% of Sperian
Protection's capital, including shares tendered by Essilor and Mrs. Ginette
Dalloz
(directly and indirectly).

By providing the resources needed to pursue growth
opportunities when they arise, Essilor believes this transaction is fully
aligned with Sperian Protection's overall development strategy.

The world leader in ophthalmic optical products, Essilor International
researches, develops, manufactures and markets around the world a wide
range of lenses to correct myopia, hyperopia, presbyopia and astigmatism.
Its flagship brands are Varilux(R), Crizal(R), Essilor(R), Definity(R) and
Xperio(TM).

Based in France, the company reported consolidated revenue of more than
EUR3.2 billion in 2009, with 34,700 employees and operations in 100
countries.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is
included in the CAC 40 index.

Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA;
Bloomberg: EI:FP.

Investor Relations and Financial Communications

Veronique Gillet - Sebastien Leroy

Phone: +33-(0)1-49-77-42-16

www.essilor.com

Investor Relations and Financial Communications: Veronique Gillet - Sebastien Leroy, Phone: +33-(0)1-49-77-42-16

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :